PRAME as an Independent Biomarker for Metastasis in Uveal Melanoma

Purpose: Uveal melanoma (UM) can be classified by gene expression profiling (GEP) into Class 1 (low metastatic risk) and Class 2 (high metastatic risk), the latter being strongly associated with mutational inactivation of the tumor suppressor BAP1. Nevertheless, a small percentage of Class 1 tumors give rise to metastatic disease. The purpose of this study was to identify biomarkers of metastasis in Class 1 tumors. Experimental Design: A total of 389 consecutive patients with UM were assigned to Class 1 or Class 2 using a prospectively validated 12-gene prognostic classifier. Selected tumors were further analyzed using global GEP and single nucleotide polymorphism microarrays. PRAME (preferentially expressed antigen in melanoma) mRNA expression was analyzed in 64 Class 1 tumors by qPCR. Results: Among Class 1 UMs, the most significant predictor of metastasis was PRAME mRNA expression (P = 0.0006). The 5-year actuarial rate of metastasis was 0% for Class1PRAME−, 38% for Class1PRAME+, and 71% for Class 2 tumors. Median metastasis-free survival for Class1PRAME+ patients was 88 months, compared to 32 months for Class 2 patients. Findings were validated using three independent datasets, including one using disomy 3 to identify low-risk UM. Chromosome copy number changes associated with Class1PRAME+ tumors included gain of 1q, 6p, 8q, and 9q and loss of 6q and 11q. PRAME expression was associated with larger tumor diameter (P = 0.05) and SF3B1 mutations (P = 0.003). Conclusions: PRAME is an independent prognostic biomarker in UM, which identifies increased metastatic risk in patients with Class 1 or disomy 3 tumors. This finding may further enhance the accuracy of prognostic testing and precision medicine for UM. Clin Cancer Res; 22(5); 1234–42. ©2016 AACR.

[1]  A. D. Dei Tos,et al.  Isolated brain metastasis of malignant choroidal melanoma 27 years after enucleation. , 1999, A M A Archives of Ophthalmology.

[2]  Steven J. M. Jones,et al.  Circos: an information aesthetic for comparative genomics. , 2009, Genome research.

[3]  A. Hinnebusch,et al.  Exome sequencing identifies recurrent somatic mutations in EIF1AX and SF3B1 in uveal melanoma with disomy 3 , 2013, Nature Genetics.

[4]  A. Bowcock,et al.  Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma , 2013, Nature Genetics.

[5]  P. Coulie,et al.  Characterization of an antigen that is recognized on a melanoma showing partial HLA loss by CTL expressing an NK inhibitory receptor. , 1997, Immunity.

[6]  O. Larsson,et al.  Concomitant loss of chromosome 3 and whole arm losses and gains of chromosome 1, 6, or 8 in metastasizing primary uveal melanoma. , 2001, Investigative ophthalmology & visual science.

[7]  David J. Wilson,et al.  Collaborative Ocular Oncology Group report number 1: prospective validation of a multi-gene prognostic assay in uveal melanoma. , 2012, Ophthalmology.

[8]  R. Bernards,et al.  A functional genetic screen identifies retinoic acid signaling as a target of histone deacetylase inhibitors , 2007, Proceedings of the National Academy of Sciences.

[9]  M Laurin Council,et al.  Oncogenic mutations in GNAQ occur early in uveal melanoma. , 2008, Investigative ophthalmology & visual science.

[10]  A. Gutin,et al.  Clinical validation of a gene expression signature that differentiates benign nevi from malignant melanoma , 2015, Journal of cutaneous pathology.

[11]  J. Harbour,et al.  A prognostic test to predict the risk of metastasis in uveal melanoma based on a 15-gene expression profile. , 2014, Methods in molecular biology.

[12]  J. Harbour,et al.  An accurate, clinically feasible multi-gene expression assay for predicting metastasis in uveal melanoma. , 2010, The Journal of molecular diagnostics : JMD.

[13]  R. Bernards,et al.  A causal role for the human tumor antigen preferentially expressed antigen of melanoma in cancer. , 2006, Cancer research.

[14]  R. Kiessling,et al.  Retinoic acid elicits cytostatic, cytotoxic and immunomodulatory effects on uveal melanoma cells , 2006, Cancer Immunology, Immunotherapy.

[15]  Bertil Damato,et al.  Current management of uveal melanoma , 2000 .

[16]  A. Bowcock,et al.  Loss of Heterozygosity of Chromosome 3 Detected with Single Nucleotide Polymorphisms Is Superior to Monosomy 3 for Predicting Metastasis in Uveal Melanoma , 2007, Clinical Cancer Research.

[17]  F. Crea,et al.  EZH2 inhibition: targeting the crossroad of tumor invasion and angiogenesis , 2012, Cancer and Metastasis Reviews.

[18]  Justis P. Ehlers,et al.  Gene Expression Profiling in Uveal Melanoma Reveals Two Molecular Classes and Predicts Metastatic Death , 2004, Cancer Research.

[19]  A. Bowcock,et al.  Frequent Mutation of BAP1 in Metastasizing Uveal Melanomas , 2010, Science.

[20]  H. Stunnenberg,et al.  The tumour antigen PRAME is a subunit of a Cul2 ubiquitin ligase and associates with active NFY promoters , 2011, The EMBO journal.

[21]  Daniel L. Chao,et al.  A molecular revolution in uveal melanoma: implications for patient care and targeted therapy. , 2014, Ophthalmology.

[22]  Sean R. Davis,et al.  NCBI GEO: archive for functional genomics data sets—update , 2012, Nucleic Acids Res..

[23]  J. O'Brien,et al.  Mutations in GNA11 in uveal melanoma. , 2010, The New England journal of medicine.

[24]  J. Harbour,et al.  Prognostic biomarkers in uveal melanoma: evidence for a stem cell-like phenotype associated with metastasis , 2008, Melanoma research.

[25]  P. Snijders,et al.  A Role for EZH2 in Silencing of IFN-γ Inducible MHC2TA Transcription in Uveal Melanoma1 , 2007, The Journal of Immunology.

[26]  A. Amir,et al.  PRAME-Specific Allo-HLA–Restricted T Cells with Potent Antitumor Reactivity Useful for Therapeutic T-Cell Receptor Gene Transfer , 2011, Clinical Cancer Research.

[27]  R. Mortara,et al.  Telomere-centromere-driven genomic instability contributes to karyotype evolution in a mouse model of melanoma. , 2010, Neoplasia.

[28]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[29]  M. Nardini,et al.  Sequence-Specific Transcription Factor NF-Y Displays Histone-like DNA Binding and H2B-like Ubiquitination , 2013, Cell.

[30]  J. Harbour,et al.  Prognostic parameters in uveal melanoma and their association with BAP1 expression , 2014, British Journal of Ophthalmology.

[31]  R. Bernards,et al.  The Human Tumor Antigen PRAME Is a Dominant Repressor of Retinoic Acid Receptor Signaling , 2005, Cell.

[32]  G. Barsh,et al.  Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi , 2010 .

[33]  R. Tibshirani,et al.  Significance analysis of microarrays applied to the ionizing radiation response , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[34]  P. Snijders,et al.  A role for EZH2 in silencing of IFN-gamma inducible MHC2TA transcription in uveal melanoma. , 2007, Journal of Immunology.